HK1025518A1 - Method of using cyclooxygenase-2 inhibitors in thetreatment and prevention of neoplasia - Google Patents

Method of using cyclooxygenase-2 inhibitors in thetreatment and prevention of neoplasia

Info

Publication number
HK1025518A1
HK1025518A1 HK00104885A HK00104885A HK1025518A1 HK 1025518 A1 HK1025518 A1 HK 1025518A1 HK 00104885 A HK00104885 A HK 00104885A HK 00104885 A HK00104885 A HK 00104885A HK 1025518 A1 HK1025518 A1 HK 1025518A1
Authority
HK
Hong Kong
Prior art keywords
neoplasia
thetreatment
cyclooxygenase
inhibitors
prevention
Prior art date
Application number
HK00104885A
Other languages
English (en)
Inventor
Karen Seibert
Jaime Masferrer
Gary B Gordon
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21843754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1025518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of HK1025518A1 publication Critical patent/HK1025518A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK00104885A 1996-10-15 2000-08-04 Method of using cyclooxygenase-2 inhibitors in thetreatment and prevention of neoplasia HK1025518A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2849496P 1996-10-15 1996-10-15
PCT/US1997/018670 WO1998016227A1 (fr) 1996-10-15 1997-10-14 Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique

Publications (1)

Publication Number Publication Date
HK1025518A1 true HK1025518A1 (en) 2000-11-17

Family

ID=21843754

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00104885A HK1025518A1 (en) 1996-10-15 2000-08-04 Method of using cyclooxygenase-2 inhibitors in thetreatment and prevention of neoplasia

Country Status (25)

Country Link
EP (3) EP1977749A1 (fr)
JP (1) JP2001503395A (fr)
KR (1) KR20000049138A (fr)
CN (2) CN1332661C (fr)
AT (2) ATE399547T1 (fr)
AU (1) AU742645B2 (fr)
BR (1) BR9712314A (fr)
CA (1) CA2267186C (fr)
CZ (1) CZ298022B6 (fr)
DE (2) DE69738815D1 (fr)
DK (2) DK1479385T3 (fr)
ES (2) ES2308068T3 (fr)
HK (1) HK1025518A1 (fr)
HU (1) HU227564B1 (fr)
IL (3) IL154501A0 (fr)
NO (1) NO326822B1 (fr)
NZ (3) NZ334921A (fr)
PT (2) PT1479385E (fr)
RO (1) RO120172B1 (fr)
RU (1) RU2239429C2 (fr)
SK (1) SK284788B6 (fr)
TR (1) TR199900827T2 (fr)
TW (1) TWI235060B (fr)
UA (1) UA67732C2 (fr)
WO (1) WO1998016227A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828718A1 (fr) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Derives heterocyclo-substitues d'acide hydroxamique utilises comme inhibiteurs de la cyclo-oxygenase-2 et de la 5-lipoxygenase
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
ATE425749T1 (de) * 1999-01-27 2009-04-15 Cornell Res Foundation Inc Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
AU5873000A (en) * 1999-06-24 2001-01-31 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors forthe treatment of inflammation
EP1206256B8 (fr) * 1999-07-29 2005-06-29 Amgen, Inc. Therapie d'association comprenant l'administration de pentafluorobenzenesulfonamides
AU1623601A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Novel compounds
EP1253921A4 (fr) * 2000-01-28 2004-10-13 Merck & Co Inc Traitement ou prevention du cancer de la prostate avec un medicament inhibiteur selectif de cox-2
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
US20020009421A1 (en) * 2000-06-01 2002-01-24 Wilder Karol J. Therapy following skin injury from exposure to ultraviolet radiation
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
CA2423154A1 (fr) 2000-09-21 2002-03-28 David Kenneth Dean Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
WO2002039958A2 (fr) 2000-11-03 2002-05-23 Tularik Inc. Therapies combinees a base de pentafluorobenzenesulfonamides et d'agents antineoplasiques
DE60236273D1 (de) 2001-05-03 2010-06-17 Cornell Res Foundation Inc Behandlung von krankheiten, die durch hpv verursacht werden
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0119477D0 (en) 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
CN100506224C (zh) * 2001-10-25 2009-07-01 诺瓦提斯公司 包含选择性环加氧酶-2抑制剂的组合
FR2835433B1 (fr) * 2002-02-01 2006-02-17 Richard Lab M Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2
TW200408621A (en) 2002-04-08 2004-06-01 Glaxo Group Ltd Compounds
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
CA2515726C (fr) * 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazoles
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
CA2600276C (fr) * 2005-03-08 2013-01-08 Mitsui Norin Co., Ltd Methodes et combinaisons polyphenol-coxib
AU2009272033B2 (en) * 2008-07-17 2011-10-13 Asahi Kasei Pharma Corporation Nitrogenated heterocyclic compound
US20110144206A1 (en) * 2008-08-22 2011-06-16 Steven Lewitzky Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity
US10525040B2 (en) 2015-06-29 2020-01-07 Nantbio, Inc. Compositions and methods of Rit1 inhibition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
KR0145953B1 (ko) 1991-07-19 1998-08-17 제임스 클리프튼 보올딩 슈퍼옥사이드의 불균화촉매로서 효과적인 질소를 포함하는 마크로사이클 릭리간드의 망간착물
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
WO1994015932A1 (fr) 1993-01-15 1994-07-21 G.D. Searle & Co. Nouveaux thiophenes 3,4-diaryle et leurs analogues utilises comme agents anti-inflammatoires
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
CA2276945C (fr) * 1993-11-30 2006-08-01 G.D. Searle & Co. Pyrazolyle benzenesulfonamide tricyclique-substitue et leurs compositions pharmaceutiques
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
EP1125932A3 (fr) 1994-07-27 2001-08-29 G.D. Searle & Co. Thiazoles substitués destinés au traitement de l'inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー．ディー．サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
EP0828718A1 (fr) * 1995-06-02 1998-03-18 G.D. SEARLE & CO. Derives heterocyclo-substitues d'acide hydroxamique utilises comme inhibiteurs de la cyclo-oxygenase-2 et de la 5-lipoxygenase
WO1997008174A1 (fr) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Enzyme de conversion d'interleukine et apoptose
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren

Also Published As

Publication number Publication date
NO991793L (no) 1999-04-15
IL165816A0 (en) 2006-01-15
CN1244122A (zh) 2000-02-09
HUP9904221A3 (en) 2000-12-28
DE69729946T2 (de) 2005-01-20
CZ298022B6 (cs) 2007-05-30
TR199900827T2 (xx) 1999-07-21
CN100558356C (zh) 2009-11-11
CA2267186C (fr) 2002-05-14
UA67732C2 (uk) 2004-07-15
CZ117199A3 (cs) 1999-07-14
SK46299A3 (en) 2000-03-13
JP2001503395A (ja) 2001-03-13
HUP9904221A2 (hu) 2000-09-28
PT932402E (pt) 2004-11-30
EP1977749A1 (fr) 2008-10-08
EP0932402B1 (fr) 2004-07-21
EP1479385B1 (fr) 2008-07-02
AU742645B2 (en) 2002-01-10
PT1479385E (pt) 2008-09-02
AU4904897A (en) 1998-05-11
RU2239429C2 (ru) 2004-11-10
BR9712314A (pt) 1999-08-31
EP1479385A1 (fr) 2004-11-24
HU227564B1 (en) 2011-08-29
NZ509755A (en) 2002-09-27
TWI235060B (en) 2005-07-01
SK284788B6 (sk) 2005-11-03
DK0932402T3 (da) 2004-11-08
CN1332661C (zh) 2007-08-22
DK1479385T3 (da) 2008-08-04
RO120172B1 (ro) 2005-10-28
WO1998016227A1 (fr) 1998-04-23
CN1660083A (zh) 2005-08-31
CA2267186A1 (fr) 1998-04-23
NO326822B1 (no) 2009-02-23
IL128568A0 (en) 2000-01-31
KR20000049138A (ko) 2000-07-25
NZ334921A (en) 2001-03-30
DE69729946D1 (de) 2004-08-26
ATE399547T1 (de) 2008-07-15
EP0932402A1 (fr) 1999-08-04
ES2308068T3 (es) 2008-12-01
ATE271385T1 (de) 2004-08-15
IL154501A0 (en) 2003-09-17
NO991793D0 (no) 1999-04-15
NZ506515A (en) 2002-05-31
DE69738815D1 (de) 2008-08-14
ES2224222T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
HK1025518A1 (en) Method of using cyclooxygenase-2 inhibitors in thetreatment and prevention of neoplasia
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
PL305646A1 (en) Substituted heterocyclic carboxylic amides, method of obtaining them and therapeutic agents containing such compounds
AU696851B2 (en) Method of treating hyperproliferative vascular disease
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
WO1999005096A3 (fr) Inhibiteurs d'urokinase
ZA926837B (en) A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
HK1025036A1 (en) Novel cryptophycin derivatives as anti-neoplastic agents
WO1999009964A3 (fr) Nouvelle composition pharmaceutique
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
GB9907571D0 (en) Compounds
CA2289017A1 (fr) Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
MY133014A (en) Method for treating copd
HK1061355A1 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
CA2301590A1 (fr) 2-aminopyridines utilisees comme inhibiteurs de la cyclo-oxygenase 2
WO2001068066A3 (fr) Composition comprenant de la camptothecine ou un derive de la camptothecine et un agent alkylant, destinee au traitement du cancer
WO1995005364A3 (fr) Inhibiteurs des transporteurs d'amine biogenes
HK1024872A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
PL318539A1 (en) Inhibition of biosynthesis
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121014